PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: rfXcel Corporation

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

AvKARE Selects rfXcel for ePedigree Compliance Based on Successful Performance Track Record - Pharmaceutical industry's most production-proven E-Pedigree Solution chosen over competitive solutions to guard AvKARE’s drug supply
AvKARE Selects rfXcel for ePedigree Compliance Based on Successful Performance Track Record

 

NewswireToday - /newswire/ - San Ramon, CA, United States, 2008/07/22 - Pharmaceutical industry's most production-proven E-Pedigree Solution chosen over competitive solutions to guard AvKARE’s drug supply.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

rfXcel Corporation, a leading provider of production-proven ePedigree Management solutions that allow manufacturers, distributors, and retailers to track the chain of custody of prescription drugs through the pharmaceutical supply chain, today announced that AvKARE has purchased rfXcel’s ePedigree Management solution to protect its supply chain from the threat of counterfeit drugs.

Based in Palaski, TN, AvKARE, is a wholesaler/manufacturer of pharmaceutical and disposable medical supplies whose corporate directive is to ship product on time, in time, every time. AvKARE utilizes a warehouse and shipping facility in Pennsylvania, and manufactures generic pharmaceuticals under its own AvKARE label.

To support compliance with existing Pedigree Laws, as well as future compliance with California’s pending 2011 ePedigree and serialization requirements, AvKARE selected rfXcel’s ePedigree Management solution. rfXcel was selected for its proven track record of successful implementations and for the positive endorsements it receives time and time again from its existing customers regarding its delivery performance.

“In our research, the performance track record of rfXcel made it an easy decision to select them as our partner in our corporate growth strategy”, said Troy Mizell, President of AvKARE. “We need a partner that we can trust and, based on our analysis, we’re convinced that rfXcel is that partner”.

“We’re excited about AvKARE’s decision to select rfXcel as their ePedigree Management partner”, said Glenn Abood, rfXcel’s Founder and CEO. “Our company was founded on the principles of providing the most capable and user-friendly product and delivering on our implementation promises. Endorsements such as this help us confirm our progress towards that end”.

About rfXcel Corporation

rfXcel (rfxcel.com) founded in 2003, is headquartered in San Ramon, CA. rfXcel is a pioneer in creating real-time supply-chain performance improvement and compliance applications for retailers, manufacturers and distributors. rfXcel solutions can be implemented today, yet have the capability to scale as infrastructure technology develops. The rfXcel management team and board are comprised of industry experts that come directly from the life sciences, technology and consumer goods industries. rfXcel was founded on the principle of providing real business value to our customers by developing solutions that solve supply chain problems that they face every business day.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: rfXcel Corporation

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


AvKARE Selects rfXcel for ePedigree Compliance Based on Successful Performance Track Record

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: James McCrory - rfXcel.com 
415-548-0618 jmccrory[.]rfxcel.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any rfXcel Corporation securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From rfXcel Corporation / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® System
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization
Sugar Element of Keratan Sulfate Halts the Progress of Emphysema Finds RIKEN
Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada
FDA Extends Review of Application for OCREVUS™ (Ocrelizumab)
MDxHealth Announces AceCGT Life Science Limited as the Exclusive Distributor for SelectMDx in Hong Kong and Macao China
Pulse Certified As A Level Four Multichannel Content Agency by Veeva Systems
BD Launches Advanced Prefillable Syringe for Higher Volume Injection of Biologics
Sartorius Announces Expansion of Sartorius Stedim Cellca
Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
BD Integrating Technology, Expertise and Services to Provide Comprehensive Medication Management
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Intrinsic Executive Search Ltd

Visit  1Click Games





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)